PRPO Precipio, Inc.
USHealthcareAs of 2026-08-20
Why PRPO matters now
Precipio, Inc. (PRPO) is a US stock in Healthcare. The latest InvestLog snapshot shows $29.43 with +5.67% on the session and $52.5M in market capitalization; recent performance reads 1-month -9.04% and YTD -2.31%.
The latest financial table shown here is Q1 2026, with revenue of $6.3M, net income of $-1.4M, and EPS of $-0.81. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 1.4%.
The latest indexable market news headline is "Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes SANDBERG RICHARD A filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.83
P/S
1.54
EV/EBITDA
47.69
DCF Value
$-263.22
FCF Yield
1.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
43.3%
Operating Margin
-6.8%
Net Margin
-3.5%
ROE
-6.7%
ROA
-4.4%
ROIC
-10.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.3M | $-1.4M | $-0.81 |
| Q4 2025 | $8.0M | $526.0K | $0.33 |
| FY 2025 | $24.0M | $-363.0K | $-0.23 |
| Q3 2025 | $6.2M | $-79.0K | $-0.05 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.30
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.